论文部分内容阅读
多发性骨髓瘤目前仍是无法治愈的恶性血液系统疾病.硼替佐米作为一种新型的蛋白酶体抑制剂,临床上可用于治疗复发性、难治性或初治的多发性骨髓瘤,而来那度胺作为一种新型免疫调节药,国外研究显示来那度胺单药或联合其他抗骨髓瘤药物对初治或复发/ 难治多发性骨髓瘤(multiple myeloma,MM)均有较好的疗效,现对其作用机制、临床应用、不良反应、药物相互作用等做一综述.“,”Multiple myeloma(MM) is a malignant plasma disease and remains incurable up to now. Bortezomib is a new proteasome inhibitor. Clinical studies demonstrat that bortezomib plays role in the treatment for relapsed,refractory and initially treated multiple myeloma.Lenalidomide,a novel analogue of thalidomide,Studies have shown that lenalidomide monotherapy or in combination with other anti-myeloma drugs could improve the survival outcomes of relapsed/refractory as well as newly diagnosed multiple myeloma (MM) patients and is generally well tolerated.This paper summarizes the mechanism,clinical application,adverse reactions and drug interactions of lenalidomide.